O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-2.08%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$10.7B
AUM Growth
+$10.7B
(-6.6%)
Cap. Flow
+$450M
Cap. Flow
% of AUM
4.22%
Top 10 Holdings %
Top 10 Hldgs %
33.33%
Holding
184
New
34
Increased
39
Reduced
24
Closed
28
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$453M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$121M |
| 3 |
Haemonetics
HAE
|
$94.6M |
| 4 |
Terns Pharmaceuticals
TERN
|
$83.4M |
| 5 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$82.9M |
Top Sells
| 1 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
$319M |
| 2 |
Prelude Therapeutics
PRLD
|
$241M |
| 3 |
Pfizer
PFE
|
$133M |
| 4 |
Biogen
BIIB
|
$125M |
| 5 |
Centene
CNC
|
$120M |
Sector Composition
| 1 | Healthcare | 95.15% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
VistaGen Therapeutics
VTGN
$113M
| $18.3M | 0.17% |
8,604,000
+1,104,000
| +15% | +$2.35M |
|
102
Galapagos
GLPG
$2.06B
| $17.8M | 0.17% |
+230,905
| New | +$17.8M |
|
103
Alignment Healthcare
ALHC
$3.23B
| $17.5M | 0.16% |
+800,000
| New | +$17.5M |
|
104
BiomX
PHGE
$14.1M
| $16.5M | 0.15% |
2,313,489
| – | – |
|
|
ALXN
105
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $15.6M | 0.15% |
102,100
-66,900
| -40% | -$10.2M |
|
|
BLU
106
DELISTED
BELLUS Health Inc.
BLU
| $15.1M | 0.14% |
3,954,800
-234,793
| -6% | -$896K |
|
107
Milestone Pharmaceuticals
MIST
$151M
| $15M | 0.14% |
2,583,821
+90,712
| +4% | +$525K |
|
108
Sarepta Therapeutics
SRPT
$1.98B
| $14.9M | 0.14% |
200,278
-338,771
| -63% | -$25.2M |
|
|
SYRS
109
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $13.7M | 0.13% |
1,837,500
+275,000
| +18% | +$2.06M |
|
110
Travere Therapeutics
TVTX
$1.75B
| $13.2M | 0.12% |
+528,100
| New | +$13.2M |
|
111
WM Technology
MAPS
$123M
| $12.9M | 0.12% |
+700,400
| New | +$12.9M |
|
112
Vaxcyte
PCVX
$4.17B
| $12.8M | 0.12% |
648,774
+18,514
| +3% | +$366K |
|
113
Alector
ALEC
$282M
| $12.3M | 0.12% |
611,478
-1,613,835
| -73% | -$32.5M |
|
114
Relay Therapeutics
RLAY
$709M
| $12.1M | 0.11% |
350,000
| – | – |
|
115
X4 Pharmaceuticals
XFOR
$70M
| $11.8M | 0.11% |
1,373,849
+287,356
| +26% | +$2.47M |
|
116
Dianthus Therapeutics
DNTH
$781M
| $11.2M | 0.11% |
+949,048
| New | +$11.2M |
|
117
ALX Oncology
ALXO
$54.6M
| $11.1M | 0.1% |
150,000
| – | – |
|
|
IMDX
118
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$73.3M
| $10.9M | 0.1% |
+2,100,000
| New | +$10.9M |
|
|
OLK
119
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $10.8M | 0.1% |
+300,000
| New | +$10.8M |
|
120
Gyre Therapeutics
GYRE
$734M
| $10.7M | 0.1% |
+2,118,600
| New | +$10.7M |
|
121
Nurix Therapeutics
NRIX
$723M
| $9.33M | 0.09% |
300,000
| – | – |
|
122
Larimar Therapeutics
LRMR
$337M
| $9.02M | 0.08% |
617,245
-269,315
| -30% | -$3.93M |
|
|
ASLN
123
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $8.44M | 0.08% |
+2,520,000
| New | +$8.44M |
|
124
Health Catalyst
HCAT
$228M
| $8.4M | 0.08% |
179,598
| – | – |
|
125
Nuvation Bio
NUVB
$1.08B
| $8.36M | 0.08% |
+800,000
| New | +$8.36M |
|